1 BTC
=
- USD
Skye Bioscience, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Skye Bioscience, Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Market Statistics
Trading Metrics
How to Buy SKYE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SKYE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSkye Bioscience presented preclinical data on nimacimab, a CB1 receptor inhibitor antibody, showing significant additive weight loss effects when combined with tirzepatide and semaglutide in diet-induced obesity mouse models. The drug demonstrated durable weight loss after treatment discontinuation and reduced weight rebound by ~80% when used as maintenance therapy post-tirzepatide discontinuation. Skye is currently conducting a Phase 2a clinical trial combining nimacimab with GLP-1R agonists.
Levi & Korsinsky has filed a securities class action lawsuit against Skye Bioscience, Inc. on behalf of shareholders who suffered losses between November 4, 2024 and October 3, 2025. The complaint alleges that defendants made false statements about the effectiveness of the company's lead product candidate, nimacimab, and overstated its clinical, regulatory, and commercial prospects. Investors who suffered losses during this period can request to be appointed as lead plaintiff by January 16, 2026.
Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects.
Rosen Law Firm is reminding investors in Jayud Global Logistics Ltd. (JYD), Skye Bioscience, Inc. (SKYE), and Klarna Group plc (KLAR) of upcoming lead plaintiff deadlines in securities class action lawsuits. The firm is encouraging affected investors to secure legal counsel to potentially recover losses from alleged fraudulent activities and misleading statements.
Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.